PDL1

It is typically requested by oncologists and healthcare providers when evaluating cancer patients, especially those with lung cancer, melanoma, bladder cancer, and other malignancies where immunotherapy may be a treatment option.

‍

These are used when healthcare providers need to assess a patient's eligibility for immunotherapy, helping determine if they are likely to respond positively to immune checkpoint inhibitors.

The tests involve analyzing a tumor tissue sample to measure the presence and quantity of the PD-L1 protein in cancer cells. This is typically done through immunohistochemical staining.